These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 8548903)

  • 1. Enhanced in vivo antithrombotic effects of endothelial cells expressing recombinant plasminogen activators transduced with retroviral vectors.
    Dichek DA; Anderson J; Kelly AB; Hanson SR; Harker LA
    Circulation; 1996 Jan; 93(2):301-9. PubMed ID: 8548903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of retroviral-mediated tissue plasminogen activator gene transfer and expression on adherence and proliferation of canine endothelial cells seeded onto expanded polytetrafluoroethylene.
    Huber TS; Welling TH; Sarkar R; Messina LM; Stanley JC
    J Vasc Surg; 1995 Dec; 22(6):795-803. PubMed ID: 8523615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seeding of vascular grafts with genetically modified endothelial cells. Secretion of recombinant TPA results in decreased seeded cell retention in vitro and in vivo.
    Dunn PF; Newman KD; Jones M; Yamada I; Shayani V; Virmani R; Dichek DA
    Circulation; 1996 Apr; 93(7):1439-46. PubMed ID: 8641034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction in vascular lesion formation by hirudin secreted from retrovirus-transduced confluent endothelial cells on vascular grafts in baboons.
    Lundell A; Kelly AB; Anderson J; Marijianowski M; Rade JJ; Hanson SR; Harker LA
    Circulation; 1999 Nov; 100(19):2018-24. PubMed ID: 10556229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction in stent and vascular graft thrombosis and enhancement of thrombolysis by recombinant Lys-plasminogen in nonhuman primates.
    Sundell IB; Marzec UM; Kelly AB; Chronos NA; Petersen LC; Hanson SR; Hedner U; Harker LA
    Circulation; 1997 Aug; 96(3):941-8. PubMed ID: 9264505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of recombinant plasminogen activator production by primate endothelial cells transduced with retroviral vectors.
    Dichek DA; Lee SW; Nguyen NH
    Blood; 1994 Jul; 84(2):504-16. PubMed ID: 8025279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retroviral vector-mediated transfer and expression of human tissue plasminogen activator gene in human endothelial and vascular smooth muscle cells.
    Ekhterae D; Stanley JC
    J Vasc Surg; 1995 Jun; 21(6):953-62. PubMed ID: 7776475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombotic effects of combining activated protein C and urokinase in nonhuman primates.
    Gruber A; Harker LA; Hanson SR; Kelly AB; Griffin JH
    Circulation; 1991 Dec; 84(6):2454-62. PubMed ID: 1835678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primates.
    Yokoyama T; Kelly AB; Marzec UM; Hanson SR; Kunitada S; Harker LA
    Circulation; 1995 Aug; 92(3):485-91. PubMed ID: 7634464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced thrombolytic and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons.
    Runge MS; Harker LA; Bode C; Ruef J; Kelly AB; Marzec UM; Allen E; Caban R; Shaw SY; Haber E; Hanson SR
    Circulation; 1996 Sep; 94(6):1412-22. PubMed ID: 8823001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. tPA, but not uPA, significantly affects antithrombotic therapy by a glycoprotein IIb/IIIa antagonist, but not by a factor Xa inhibitor.
    Nishida M; Matsuno H; Kozawa O; Ueshima S; Matsuo O; Collen D; Uematsu T
    J Cardiovasc Pharmacol; 2000 Dec; 36(6):770-5. PubMed ID: 11117378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin.
    Kelly AB; Maraganore JM; Bourdon P; Hanson SR; Harker LA
    Proc Natl Acad Sci U S A; 1992 Jul; 89(13):6040-4. PubMed ID: 1385867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RGDV peptide selectively inhibits platelet-dependent thrombus formation in vivo. Studies using a baboon model.
    Cadroy Y; Houghten RA; Hanson SR
    J Clin Invest; 1989 Sep; 84(3):939-44. PubMed ID: 2760221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo retention of endothelial cells adenovirally transduced with tissue-type plasminogen activator and seeded onto expanded polytetrafluoroethylene.
    Kimura H; Sakata Y; Hamada H; Yoshida Y; Sato O; Deguchi J; Sugawara Y; Makuuchi M; Miyata T
    J Vasc Surg; 2000 Aug; 32(2):353-63. PubMed ID: 10917996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin-independent antithrombotic effects of acutely attached cultured endothelial cells on endarterectomized arteries.
    Krupski WC; Bass A; Anderson JS; Kelly AB; Harker LA
    Surgery; 1990 Aug; 108(2):283-90; discussion 290-1. PubMed ID: 2382225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition.
    Pinsky DJ; Liao H; Lawson CA; Yan SF; Chen J; Carmeliet P; Loskutoff DJ; Stern DM
    J Clin Invest; 1998 Sep; 102(5):919-28. PubMed ID: 9727060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual cell seeding and the use of zymogen tissue plasminogen activator to improve cell retention on polytetrafluoroethylene grafts.
    Yu H; Wang Y; Eton D; Rowe VL; Terramani TT; Cramer DV; Starnes VA; Weaver FA
    J Vasc Surg; 2001 Aug; 34(2):337-43. PubMed ID: 11496288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of neointima formation with tissue-type plasminogen activator.
    Hilfiker PR; Waugh JM; Li-Hawkins JJ; Kuo MD; Yuksel E; Geske RS; Cifra PN; Chawla M; Weinfeld AB; Thomas JW; Shenaq SM; Dake MD
    J Vasc Surg; 2001 Apr; 33(4):821-8. PubMed ID: 11296338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-level expression of recombinant human tPA in cultivated canine endothelial cells under varying conditions of retroviral gene transfer.
    Podrazik RM; Whitehill TA; Ekhterae D; Williams WD; Messina LM; Stanley JC
    Ann Surg; 1992 Oct; 216(4):446-52; discussion 453. PubMed ID: 1417194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasminogen activator inhibitor-1 in neointima of vein grafts: its role in reduced fibrinolytic potential and graft failure.
    Kauhanen P; Sirén V; Carpén O; Vaheri A; Lepäntalo M; Lassila R
    Circulation; 1997 Sep; 96(6):1783-9. PubMed ID: 9323062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.